Business Description
Marker Therapeutics Inc
NAICS : 325414
SIC : 2834
ISIN : US57055L2060
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.02 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.53 | |||||
Debt-to-EBITDA | -0.52 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -29.68 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34.2 | |||||
3-Year EPS without NRI Growth Rate | 36.1 | |||||
3-Year FCF Growth Rate | 33.1 | |||||
3-Year Book Growth Rate | -33.6 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.26 | |||||
9-Day RSI | 50.43 | |||||
14-Day RSI | 50.31 | |||||
6-1 Month Momentum % | 55.65 | |||||
12-1 Month Momentum % | 55.65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.57 | |||||
Quick Ratio | 5.57 | |||||
Cash Ratio | 4.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.6 | |||||
Shareholder Yield % | 2.93 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -437.83 | |||||
Net Margin % | -235.34 | |||||
FCF Margin % | -469.44 | |||||
ROE % | -48.28 | |||||
ROA % | -34.06 | |||||
ROIC % | -181.06 | |||||
ROC (Joel Greenblatt) % | -85.89 | |||||
ROCE % | -77.26 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 10.97 | |||||
PB Ratio | 2.79 | |||||
Price-to-Tangible-Book | 2.79 | |||||
EV-to-EBIT | -1.35 | |||||
EV-to-EBITDA | -1.45 | |||||
EV-to-Revenue | 5.92 | |||||
EV-to-Forward-Revenue | 0.56 | |||||
EV-to-FCF | -1.27 | |||||
Price-to-Net-Current-Asset-Value | 2.79 | |||||
Price-to-Net-Cash | 3.25 | |||||
Earnings Yield (Greenblatt) % | -74.06 | |||||
FCF Yield % | -42.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Marker Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 3.269 | ||
EPS (TTM) (€) | -0.876 | ||
Beta | 0.67 | ||
Volatility % | 49.86 | ||
14-Day RSI | 50.31 | ||
14-Day ATR (€) | 0.14281 | ||
20-Day SMA (€) | 4.018 | ||
12-1 Month Momentum % | 55.65 | ||
52-Week Range (€) | 2.814 - 4.66 | ||
Shares Outstanding (Mil) | 8.9 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Marker Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Marker Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Marker Therapeutics Inc Frequently Asked Questions
What is Marker Therapeutics Inc(FRA:GX1)'s stock price today?
When is next earnings date of Marker Therapeutics Inc(FRA:GX1)?
Does Marker Therapeutics Inc(FRA:GX1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |